Ensuring timely, equitable, and comprehensive care

Severe asthma disproportionately contributes to high levels of illness and death and drives health system costs. It is responsible for at least 50% of the total costs of asthma, despite only accounting for approximately 3–10% of cases.1 2 Especially when uncontrolled, severe asthma generates substantial costs due to lost productivity, premature death, and high use of healthcare resources.1 For example, a Canadian study estimated that the cost of managing severe asthma is ten times that of managing mild asthma.3 More than half of people living with severe asthma live with at least three other conditions,4 which further increases health system costs.


References:

  1. Nunes C, Pereira AM, Morais-Almeida M. 2017. Asthma Res Pract: 10.1186/s40733-016-0029-3
  2. Hekking PW, Wener RR, Amelink M, et al. 2015. J Allergy Clin Immunol 135(4): 896-902
  3. Sadatsafavi M, Lynd L, Marra C. 2010. Can Respir J 17(2): 74-80
  4. Scelo G, Torres-Duque CA, Maspero J, et al. 2024. Ann Allergy Asthma Immunol 132(1): 42-53
  5. Price DB, Trudo F, Voorham J, et al. 2018. J Asthma Allergy 11: 193-204
  6. British National Formulary. https://bnf.nice.org.uk/treatment-summaries/corticosteroids-generaluse/ [Accessed 10/04/24]
  7. Haughney J, Winders TA, Holmes S, et al. 2020. Adv Ther 37(9): 3645-59
  8. Global Initiative for Asthma (GINA). 2023. Global Strategy for Asthma Management and Prevention.
  9. Chung KF, Wenzel SE, Brozek JL, et al. 2014. Eur Respir J 43(2): 343-73